In contrast, a similar recently published meta-analysis [53] made no assessment of the influence of ERCC1 status in patients who did not receive chemotherapy or SCLC patients, did not account for adjusting and made no assessment of methodological differences between contributing studies, failed to use the published HR and CIs for one study which compromised assessment of publication bias, used fixed effect meta-analyses despite significant between-study heterogeneity, and included potentially overlapping datasets. This evidence concerns the gene ERCC1 and small cell lung carcinoma.